The Vall d’Hebron Barcelona Hospital Campus and Biocat held a new session of the ATMP Catalonia Series, titled ‘ATMPs: From…
NOTICIAS
VHIO played a prominent role at the ESMO Targeted Anticancer Therapies (TAT) congress, one of the leading international forums in…
The global phase 3 MANEUVER study was designed to evaluate the efficacy and safety of pimicotinib, an oral, highly selective…
The Department of Health of the Government of Catalonia has awarded 36 grants to intensify research activity among health science…
This year, Vall d’Hebron Barcelona Hospital Campus commemorated World Cancer Day with a public talk at Palau Robert, coinciding with…
The Carlos III Health Institute (ISCIII) has published the final resolution of grant awards corresponding to the 2025 Strategic Action…
The new multi-sector public-private partnership funded by the Innovative Health Initiative (IHI) brings together 18 partners across nine countries, including…
Researchers from the Hospital del Mar Research Institute and the VHIO’s Growth Factors Group have demonstrated, in animal models, the…
The report, published in Nature, reveals that polyamines bind to specific domains in proteins and operate as a metabolic shield…
The BREAKWATER open-label, randomized phase 3 study was designed to evaluate first-line treatment with targeted therapies encorafenib and cetuximab plus…
